content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  <P STYLE="margin: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><B>Registration No. ______________</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange
  Commission on June 22, 2020</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>UNITED STATES</B></FONT><BR>
  <FONT STYLE="font-size: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
  <FONT STYLE="font-size: 10pt">WASHINGTON, DC 20549</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
  UNDER<BR>
  THE SECURITIES ACT OF 1933</B></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>BiondVax Pharmaceuticals
  Ltd.</B></FONT><BR>
  <FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter) </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>State
      of Israel</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Not
      Applicable</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(State or other jurisdiction
      of</FONT></TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification
      No.)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">incorporation or organization)</FONT></TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BiondVax Pharmaceuticals Ltd.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jerusalem BioPark, 2<SUP>nd</SUP> Floor</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Hadassah Ein Kerem Campus</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jerusalem, Israel</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tel: +972-8-930-2529</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fax: +972-8-930-2531</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of Principal Executive Offices)<BR>
  <BR></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The 2005 Israeli Share Option Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><BR>
  The 2018 Israeli Share Option Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Full title of the plan)<BR>
  <BR></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Puglisi &amp; Associates<BR>
  850 Library Avenue, Suite 204<BR>
  Newark, Delaware</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">(Name and address of agent
  for service)<BR>
  <BR></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>+1 (302) 738-6680<BR>
  </B>(Telephone number, including area code, of agent for service)<BR>
  <BR></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>Copies to: </I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Perry Wildes</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Joshua Ravitz</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Gross, Kleinhendler,
  Hodak, Halevy,</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Greenberg, Shenhav
  &amp; Co.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>One Azrieli Center</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Tel Aviv 6701101,
  Israel</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>+972 (3) 607-4444</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 69%; padding-right: -35.7pt; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Large
      Accelerated Filer &#9744;</FONT></TD>
      <TD STYLE="width: 31%; padding-right: -35.7pt; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Accelerated
      Filer &#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: -35.8pt; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Non-Accelerated
  Filer &#9744;</FONT></TD>
      <TD STYLE="padding-right: -35.8pt; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Smaller
      reporting company</FONT> &#9744;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Emerging growth company
      &#9746; </FONT></TD></TR>
  </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by
  check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR STYLE="clear: both"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0; padding-left: 0; font-weight: bold; text-align: left">Title
      of securities to be registered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount<BR>
  
      to be<BR> registered</B><SUP>(1)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proposed maximum<BR> offering
      price<BR> per share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proposed maximum<BR> aggregate
      offering<BR> price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount of<BR> registration<BR>
      fee</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"><FONT STYLE="font-size: 10pt">Ordinary
      shares, no par value, deposited as American Depositary Shares represented by American Depositary Receipts<SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,763,920</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.468</TD><TD STYLE="width: 1%; text-align: left">(4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,697,514.56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">350.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Ordinary shares,
      no par value, deposited as American Depositary Shares represented by American Depositary Receipts<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,726,680</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.468</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">808,086.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">104.89</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Ordinary shares,
      no par value, deposited as American Depositary Shares represented by American Depositary Receipts<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,509,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">(7)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.2375</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">(8)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,345,982.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">693.91</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,000,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,851,583.30</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,148.94</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule
                                           416(a) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
                                           this registration statement shall also cover any additional ordinary shares, no par value
                                           (&ldquo;Ordinary Shares&rdquo;) of BiondVax Pharmaceutical Ltd. (the &ldquo;Company&rdquo;)
                                           that become issuable under the 2005 Israeli Share Option Plan and the 2018 Israeli Share
                                           Option Plan (collectively, the &ldquo;Plan&rdquo;) by reason of any stock dividend, stock
                                           split, or other similar transaction.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">American Depositary
                                           Shares (&ldquo;ADSs&rdquo;), evidenced by American Depositary Receipts, issuable upon
                                           deposit of the Ordinary Shares registered hereby, are registered on a separate registration
                                           statement on Form F-6 (File No. 333-203333). Each ADS represents forty (40) Ordinary
                                           Shares.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Represents the number
                                           of additional Ordinary Shares reserved for future issuance under the Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h)
                                           under the Securities Act, and based on the average of the high and low prices of the
                                           ADSs as reported on The Nasdaq Capital Market on June 11, 2020.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Represents Ordinary
                                           Shares issuable upon the vesting and settlement of outstanding restricted share units
                                           granted under the Plan.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h)
                                           under the Securities Act, and based on the average of the high and low prices of the
                                           Ordinary Shares as reported on The Nasdaq Capital Market on June 11, 2020.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(7)</TD><TD STYLE="text-align: justify">Represents Ordinary
                                           Shares issuable upon exercise of outstanding options with fixed exercise prices under
                                           the Plan, with a weighted average exercise price of $5.72 per ADS.</TD>
  </TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(8)</TD><TD STYLE="text-align: justify">Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rule 457(h) under the Securities
                                           Act and based on the weighted average price at which such options may be exercised.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 45pt"><FONT STYLE="font-size: 10pt">ITEM 1.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">PLAN
                                           INFORMATION.* </FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 45pt"><FONT STYLE="font-size: 10pt">ITEM 2.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">REGISTRANT
                                           INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION. * </FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Information required
                                           by Part I to be contained in the Section 10(a) prospectus is omitted from this registration
                                           statement in accordance with Rule 428 under the Securities Act of 1933, as amended, or
                                           the Securities Act, and the Introductory Note to Part I of Form S-8.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 49.85pt"><FONT STYLE="font-size: 10pt">ITEM 3.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">INCORPORATION
                                           OF DOCUMENTS BY REFERENCE </FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following documents
  filed with or furnished to the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) by BiondVax Pharmaceuticals
  Ltd., a company organized under the laws of Israel (the &ldquo;<U>Company</U>&rdquo; or the &ldquo;<U>Registrant</U>&rdquo;),
  are incorporated herein by reference and made a part hereof:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Company&rsquo;s Annual Report
                                           for the year ended December 31, 2019 on <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020014759/f20f2019_biondvaxpharma.htm">Form 20-F</A> filed with the Commission on June 12,
                                           2020;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the Company&rsquo;s reports on Form
                                           6-K furnished to the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020000828/f6k0120b_biondvax.htm">January 13, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020001166/f6k011620c_biondvaxpharma.htm">January 16, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020002666/f6k020520_biondvax.htm">February 5, 2020</A>,
                                           <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020003063/f6k021020_biondvaxpharma.htm">February 10, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020004711/ea119006-6k_biondvax.htm">February 25, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020006841/ea119806-6k_biondvax.htm">March 19, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020007261/ea119942-6k_biondvax.htm">March 24, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020010562/ea121230-6k_biondvaxpharma.htm">April 30, 2020</A>,
                                           <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020010866/ea121334-6k_biondvaxpharma.htm">May 4, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020013023/ea122166-6k_biondvax.htm">May 20, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020014562/ea122885-6k_biondvaxpharma.htm">June 10, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020014762/ea122989-6k_biondvax.htm">June 12, 2020</A>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the description of the Company&rsquo;s
                                           American Depositary Shares, each representing forty (40) ordinary shares, no par value,
                                           included in the registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390015002835/f8a12b_biondvax.htm">Form&nbsp;8-A</A> filed on April 20, 2015 (File
                                           No.&nbsp;001-37353) under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange
                                           Act</U>&rdquo;), including any amendment or report filed for the purpose of updating
                                           such description.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All documents or reports
  subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and to the extent designated
  therein, certain reports on Form 6-K, furnished by the Company, after the date of this Registration Statement and prior to the
  filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all
  securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement
  and to be part hereof from the date of filing of such documents or reports. Any statement in a document or report incorporated
  or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration
  Statement to the extent that a statement contained herein or in any other subsequently filed document or report which also is
  or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 49.85pt">ITEM 4.</TD><TD STYLE="text-align: left">DESCRIPTION OF SECURITIES</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 49.85pt">ITEM 5.</TD><TD STYLE="text-align: left">INTERESTS OF NAMED EXPERTS AND COUNSEL</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 49.85pt">ITEM 6.</TD><TD STYLE="text-align: left">INDEMNIFICATION OF DIRECTORS AND
                                           OFFICERS</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
  Law, 5759-1999, or the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the
  duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part,
  for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation
  is included in its articles of association. Our&nbsp;amended and restated articles of association include such a provision. The
  company may not exculpate in advance a director from liability arising from a breach of his or her duty of care in connection
  with a prohibited dividend or distribution to shareholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 4; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As permitted under the
  Israeli Companies Law, our amended and restated articles of association provide that we may indemnify an office holder in respect
  of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance
  of an event or following an event:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a
                                           monetary liability incurred by or imposed on the office holder in favor of another person
                                           pursuant to a court judgment, including pursuant to a settlement confirmed as judgment
                                           or arbitrator&rsquo;s decision approved by a competent court. However, if an undertaking
                                           to indemnify an office holder with respect to such liability is provided in advance,
                                           then such an undertaking must be limited to events which, in the opinion of the board
                                           of directors, can be foreseen based on the company&rsquo;s activities when the undertaking
                                           to indemnify is given, and to an amount or according to criteria determined by the board
                                           of directors as reasonable under the circumstances, and such undertaking shall detail
                                           the abovementioned foreseen events and amount or criteria;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reasonable litigation expenses,
                                           including reasonable attorneys&rsquo; fees, which were incurred by the office holder
                                           as a result of an investigation or proceeding filed against the office holder by an authority
                                           authorized to conduct such investigation or proceeding, provided that such investigation
                                           or proceeding was (i) concluded without the filing of an indictment against such office
                                           holder and without the imposition on him of any monetary obligation in lieu of a criminal
                                           proceeding, (ii) concluded without the filing of an indictment against the office holder
                                           but with the imposition of a monetary obligation on the office holder in lieu of criminal
                                           proceedings for an offense that does not require proof of criminal intent, or (iii) in
                                           connection with a monetary sanction;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reasonable litigation expenses,
                                           including attorneys&rsquo; fees, incurred by the office holder or which were imposed
                                           on the office holder by a court (i) in a proceeding instituted against him or her by
                                           the company, on its behalf, or by a third party, (ii) in connection with criminal indictment
                                           of which the office holder was acquitted, or (iii) in a criminal indictment of which
                                           the office holder was convicted of an offense that does not require proof of criminal
                                           intent;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">expenses he or she incurs
                                           as a result of administrative proceedings that may be instituted against him or her under
                                           Israeli securities laws, if applicable, and payments made to injured persons under specific
                                           circumstances thereunder; and</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any other matter in respect
                                           of which it is permitted or will be permitted under applicable law to indemnify an office
                                           holder in the company.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">As permitted under the
  Israeli Companies Law, our amended and restated articles of association provide that we may insure an office holder against the
  following liabilities incurred for acts performed by him or her as an office holder:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a breach of the duty of loyalty
                                           to the company, provided that the office holder acted in good faith and had a reasonable
                                           basis to believe that the act would not harm the company;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a breach of duty of care to
                                           the company or to another person, to the extent such a breach arises out of the negligent
                                           conduct of the office holder;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a monetary liability imposed
                                           on the office holder in favor of a third party;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">expenses he or she incurs
                                           as a result of administrative proceedings that may be instituted against him or her under
                                           the Israeli securities laws if applicable, and payments made to injured persons under
                                           specific circumstances thereunder; and</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any other matter in respect
                                           of which it is permitted or will be permitted under applicable law to insure the liability
                                           of an office holder in the company.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">Under the Israeli Companies
  Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a breach of the duty of loyalty,
                                           except for indemnification and insurance for a breach of the duty of loyalty to the company
                                           to the extent that the office holder acted in good faith and had a reasonable basis to
                                           believe that the act would not prejudice the company;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a breach of duty of care committed
                                           intentionally or recklessly, excluding a breach arising out of the negligent conduct
                                           of the office holder;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">an act or omission committed
                                           with intent to derive illegal personal benefit; or</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a fine or forfeit levied against
                                           the office holder.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">Under the Israeli Companies
  Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board
  of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling
  shareholders have a personal interest, also by the shareholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt">Our articles of association
  permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. The
  Company has obtained directors&rsquo; and officers&rsquo; liability insurance for the benefit of its office holders and intends
  to continue to maintain such coverage and pay all premiums thereunder up to to the fullest extent permitted by the Israeli Companies
  Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we have entered
  into agreements with each of our directors and executive officers exculpating them, to the fullest extent permitted by law and
  our articles of association, and undertaking to indemnify them to the fullest extent permitted by law and our articles of association.
  This indemnification is limited to events determined as foreseeable by the board of directors based on our activities, and to
  an amount or according to criteria determined by the board of directors as reasonable under the circumstances. The maximum indemnification
  amount set forth in such agreements is limited to an amount which shall not exceed 25% of our net assets based on our most recently
  audited or reviewed financial statements prior to actual payment of the indemnification amount. Such maximum amount is in addition
  to any amount paid (if paid) under insurance and/or by a third-party pursuant to an indemnification arrangement. In the opinion
  of the SEC, indemnification of directors and office holders for liabilities arising under the Securities Act of 1933, however,
  is against public policy and therefore unenforceable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 49.85pt">ITEM 7.</TD><TD STYLE="text-align: left">EXEMPTION FROM REGISTRATION CLAIMED</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 49.85pt"><FONT STYLE="font-size: 10pt">ITEM 8.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">EXHIBITS.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in">See Exhibit Index following
  the signature page.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 49.85pt"><FONT STYLE="font-size: 10pt">ITEM 9.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">UNDERTAKINGS</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The undersigned Registrant hereby
                                           undertakes:</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">To file, during any period in
                                           which offers or sales are being made, a post-effective amendment to this registration
                                           statement:</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 72.3pt"></TD><TD STYLE="width: 17.7pt">(i)</TD><TD STYLE="text-align: justify">to include any prospectus required
                                           by Section 10(a)(3) of the Securities Act;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 72.3pt"></TD><TD STYLE="width: 17.7pt">(ii)</TD><TD STYLE="text-align: justify">to reflect in the prospectus
                                           any facts or events arising after the effective date of the Registration Statement (or
                                           the most recent post-effective amendment thereof) which, individually or in the aggregate,
                                           represent a fundamental change in the information set forth in the Registration Statement;
                                           and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 72.3pt"></TD><TD STYLE="width: 17.7pt">(iii)</TD><TD STYLE="text-align: justify">to include any material information
                                           with respect to the plan of distribution not previously disclosed in the Registration
                                           Statement or any material change to such information in the Registration Statement;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 89.85pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify"><I>provided, however,</I> that
  paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment
  by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13
  or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36.3pt"></TD><TD STYLE="width: 17.7pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That,
                                           for the purpose of determining any liability under the Securities Act, each such post-effective
                                           amendment shall be deemed to be a new registration statement relating to the securities
                                           offered therein, and the offering of such securities at that time shall be deemed to
                                           be the initial <I>bona fide</I> offering thereof</FONT>.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify; text-indent: -17.85pt"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 36.3pt"></TD><TD STYLE="width: 17.7pt">(3)</TD><TD STYLE="text-align: justify">To remove from registration by
                                           means of a post-effective amendment any of the securities being registered which remain
                                           unsold at the termination of the offering.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 53.85pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The undersigned Registrant hereby
                                           undertakes that, for purposes of determining any liability under the Securities Act,
                                           each filing of the Registrant&rsquo;s annual report pursuant to Section 13(a) or Section
                                           15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit
                                           plan&rsquo;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated
                                           by reference in the registration statement shall be deemed to be a new registration statement
                                           relating to the securities offered therein, and the offering of such securities at that
                                           time shall be deemed to be the initial <I>bona fide</I> offering thereof.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Insofar as indemnification for
                                           liabilities arising under the Securities Act may be permitted to directors, officers
                                           and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise,
                                           the Registrant has been advised that in the opinion of the Securities and Exchange Commission
                                           such indemnification is against public policy as expressed in the Securities Act and
                                           is, therefore, unenforceable. In the event that a claim for indemnification against such
                                           liabilities (other than the payment by the Registrant of expenses incurred or paid by
                                           a director, officer or controlling person of the Registrant in the successful defense
                                           of any action, suit or proceeding) is asserted by such director, officer or controlling
                                           person in connection with the securities being registered, the Registrant will, unless
                                           in the opinion of its counsel the matter has been settled by controlling precedent, submit
                                           to a court of appropriate jurisdiction the question whether such indemnification by it
                                           is against public policy as expressed in the Securities Act and will be governed by the
                                           final adjudication of such issue.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>EXHIBIT INDEX</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Exhibit<BR>
      Number</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 91%; text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020014759/f20f2019ex1-1_biondvax.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Articles of Association of the Registrant (incorporated by reference to Exhibit 1.1 of the annual report on Form 20-F filed with the Securities and Exchange Commission on June 12, 2020).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="ea123060ex5-1_biondvax.htm"><FONT STYLE="font-size: 10pt">Opinion of Pearl Cohen Zedek Latzer Baratz.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">5.2</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="ea123060ex5-2_biondvax.htm"><FONT STYLE="font-size: 10pt">Opinion of Gross,&nbsp;Kleinhendler, Hodak,&nbsp;Halevy,&nbsp;Greenberg, Shenhav&nbsp;&amp; Co.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="ea123060ex5-1_biondvax.htm"><FONT STYLE="font-size: 10pt">Consent of &nbsp;Pearl Cohen Zedek Latzer Baratz (included in Exhibit 5.1).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="ea123060ex5-2_biondvax.htm"><FONT STYLE="font-size: 10pt">Consent of Gross,&nbsp;Kleinhendler, Hodak,&nbsp;Halevy,&nbsp;Greenberg, Shenhav&nbsp;&amp; Co. (included in Exhibit 5.2).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">23.3</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="ea123060ex23-3_biondvax.htm"><FONT STYLE="font-size: 10pt">Consent of Kost Forer Gabbay and Kasirer, Certified Public Accountant (Isr.), a member of Ernst &amp; Young Global.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="#sig"><FONT STYLE="font-size: 10pt">Power of Attorney (included on signature page).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed"><A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020014759/f20f2019ex4-1_biondvax.htm"><FONT STYLE="font-size: 10pt">The 2005 Israeli Share Option Plan (incorporated by reference to Exhibit 4.1 of the annual report on Form 20-F filed with the Securities and Exchange Commission on June 12, 2020).</FONT></A></TD></TR>
  
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: justify; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
  <TD STYLE="width: 8%; text-align: left">99.2</TD>
      <TD STYLE="width: 1%">&nbsp;</TD><TD STYLE="text-align: justify; width: 91%"><A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020014759/f20f2019ex4-2_biondvax.htm">The 2018 Israeli Share Option Plan (incorporated by reference to Exhibit 4.2 of the annual report on Form 20-F filed with the Securities and Exchange Commission on June 12, 2020).</A></TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.75pt; text-align: left; text-indent: -84.75pt">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 6pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="sig"></A>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 6pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
  duly authorized, in the City of Jerusalem, State of Israel, on this 22nd   day of June, 2020.</P>
  
  <P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>BiondVax Pharmaceuticals
      Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed; width: 60%">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed; width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed; width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-bottom: 1.5pt; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Ron Babecoff <I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Ron Babecoff</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Chief Executive
      Officer</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0 0 0 198.45pt; text-align: left">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">KNOW ALL BY THESE PRESENTS,
  that each individual whose signature appears below constitutes and appoints Ron Babecoff and Uri Ben Or, and each of them, his
  true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him and in his name, place
  and stead, in any and all capacities, to sign this registration statement and any and all future amendments (including post-effective
  amendments) to the registration statement, and to file the same with all exhibits thereto, and all documents in connection therewith,
  with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, and each of them, full power and authority
  to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents
  and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any
  of them, or their or his substitute, may lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, as amended this registration statement has been signed by the following persons in the capacities
  and on the dates indicated:</P>
  
  <P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><B>&nbsp;</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 28%; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Signatures</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 52%; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 18%; text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Mark Germain</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Chairman of the Board of Directors</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Mark Germain</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Ron Babecoff</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Chief Executive Officer and
      Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Ron Babecoff</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Uri Ben Or</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Uri Ben Or</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Avner Rotman</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Avner Rotman</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Yael Margolin</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Yael Margolin</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      George H. Lowell</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">George H. Lowell</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Morris Laster</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Morris Laster</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Ruth Ben Yakar</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Ruth Ben Yakar</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Issac Devash</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Issac Devash</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Adi Raviv</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Adi Raviv</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/
      Samuel Moed</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Samuel Moed</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: center; direction: ltr; unicode-bidi: embed">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD COLSPAN="2" STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt"><B>Puglisi &amp;
      Associates</B></FONT></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD COLSPAN="2" STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Authorized U.S.
      Representative</FONT></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 6%; text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="width: 34%; text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-bottom: 1.5pt; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">&nbsp;/s/
      Donald Puglisi</FONT></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Donald Puglisi</FONT></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Managing Director </FONT></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD COLSPAN="2" STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">June 22, 2020</FONT></TD>
      <TD>&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 198.45pt; text-align: left">&nbsp;</P>
  
  
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">7</P>
  
  <P STYLE="margin: 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="margin: 0"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea123060-s8_biondvaxpharma.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 98835}]
metadata_filer: {"company-data": {"conformed-name": "BiondVax Pharmaceuticals Ltd.", "cik": "0001611747", "assigned-sic": "2836", "irs-number": "000000000", "state-of-incorporation": "L3", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-239344", "film-number": "20978080"}, "business-address": {"street1": "14 EINSTEIN ST.", "city": "NES-ZIONA", "state": "L3", "zip": "74036", "phone": "972-8-9302529"}, "mail-address": {"street1": "14 EINSTEIN ST.", "city": "NES-ZIONA", "state": "L3", "zip": "74036"}}
text: Registration No. ______________
  As filed with the Securities and Exchange
  Commission on June 22, 2020
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, DC 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  BiondVax Pharmaceuticals
  Ltd.
  (Exact name of registrant as specified in its charter)
  State
      of Israel
  Not
      Applicable
  (State or other jurisdiction
      of
  (I.R.S. Employer Identification
      No.)
  incorporation or organization)
  BiondVax Pharmaceuticals Ltd.
  Jerusalem BioPark, 2
  nd
  Floor
  Hadassah Ein Kerem Campus
  Jerusalem, Israel
  Tel: +972-8-930-2529
  Fax: +972-8-930-2531
  (Address of Principal Executive Offices)
  The 2005 Israeli Share Option Plan
  (Full title of the plan)
  The 2018 Israeli Share Option Plan
  (Full title of the plan)
  Puglisi & Associates
  850 Library Avenue, Suite 204
  Newark, Delaware
  (Name and address of agent
  for service)
  +1 (302) 738-6680
  (Telephone number, including area code, of agent for service)
  Copies to:
  Perry Wildes
  Joshua Ravitz
  Gross, Kleinhendler,
  Hodak, Halevy,
  Greenberg, Shenhav
  & Co.
  One Azrieli Center
  Tel Aviv 6701101,
  Israel
  +972 (3) 607-4444
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
  company. See the definitions of "large accelerated filer", "accelerated filer," "smaller reporting company"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large
      Accelerated Filer ☐
  Accelerated
      Filer ☐
  Non-Accelerated
  Filer ☐
  Smaller
      reporting company
  ☐
  Emerging growth company
      ☒
  If an emerging growth company, indicate by
  check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
  accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  CALCULATION OF REGISTRATION FEE
  Title
      of securities to be registered
  Amount
  to be
  registered
  (1)
  Proposed maximum
  offering
      price
  per share
  Proposed maximum
  aggregate
      offering
  price
  Amount of
  registration
  fee
  Ordinary
      shares, no par value, deposited as American Depositary Shares represented by American Depositary Receipts
  (2)
  5,763,920
  (3)
  $
  0.468
  (4)
  $
  2,697,514.56
  $
  350.14
  Ordinary shares,
      no par value, deposited as American Depositary Shares represented by American Depositary Receipts
  (2)
  1,726,680
  (5)
  $
  0.468
  (6)
  $
  808,086.24
  $
  104.89
  Ordinary shares,
      no par value, deposited as American Depositary Shares represented by American Depositary Receipts
  (2)
  22,509,400
  (7)
  $
  0.2375
  (8)
  $
  5,345,982.50
  $
  693.91
  Total
  30,000,000
  $
  8,851,583.30
  $
  1,148.94
  (1)
  Pursuant to Rule
                                           416(a) under the Securities Act of 1933, as amended (the "Securities Act"),
                                           this registration statement shall also cover any additional ordinary shares, no par value
                                           ("Ordinary Shares") of BiondVax Pharmaceutical Ltd. (the "Company")
                                           that become issuable under the 2005 Israeli Share Option Plan and the 2018 Israeli Share
                                           Option Plan (collectively, the "Plan") by reason of any stock dividend, stock
                                           split, or other similar transaction.
  (2)
  American Depositary
                                           Shares ("ADSs"), evidenced by American Depositary Receipts, issuable upon
                                           deposit of the Ordinary Shares registered hereby, are registered on a separate registration
                                           statement on Form F-6 (File No. 333-203333). Each ADS represents forty (40) Ordinary
                                           Shares.
  (3)
  Represents the number
                                           of additional Ordinary Shares reserved for future issuance under the Plan.
  (4)
  Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h)
                                           under the Securities Act, and based on the average of the high and low prices of the
                                           ADSs as reported on The Nasdaq Capital Market on June 11, 2020.
  (5)
  Represents Ordinary
                                           Shares issuable upon the vesting and settlement of outstanding restricted share units
                                           granted under the Plan.
  (6)
  Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h)
                                           under the Securities Act, and based on the average of the high and low prices of the
                                           Ordinary Shares as reported on The Nasdaq Capital Market on June 11, 2020.
  (7)
  Represents Ordinary
                                           Shares issuable upon exercise of outstanding options with fixed exercise prices under
                                           the Plan, with a weighted average exercise price of $5.72 per ADS.
  (8)
  Estimated solely
                                           for purposes of calculating the registration fee pursuant to Rule 457(h) under the Securities
                                           Act and based on the weighted average price at which such options may be exercised.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS
  ITEM 1.
  PLAN
                                           INFORMATION.*
  ITEM 2.
  REGISTRANT
                                           INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION. *
  *
  Information required
                                           by Part I to be contained in the Section 10(a) prospectus is omitted from this registration
                                           statement in accordance with Rule 428 under the Securities Act of 1933, as amended, or
                                           the Securities Act, and the Introductory Note to Part I of Form S-8.
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION
  STATEMENT
  ITEM 3.
  INCORPORATION
                                           OF DOCUMENTS BY REFERENCE
  The following documents
  filed with or furnished to the Securities and Exchange Commission (the "
  Commission
  ") by BiondVax Pharmaceuticals
  Ltd., a company organized under the laws of Israel (the "
  Company
  " or the "
  Registrant
  "),
  are incorporated herein by reference and made a part hereof:
  (a)
  the Company's Annual Report
                                           for the year ended December 31, 2019 on
  Form 20-F
  filed with the Commission on June 12,
                                           2020;
  (b)
  the Company's reports on Form
                                           6-K furnished to the Commission on
  January 13, 2020
  ,
  January 16, 2020
  ,
  February 5, 2020
  ,
  February 10, 2020
  ,
  February 25, 2020
  ,
  March 19, 2020
  ,
  March 24, 2020
  ,
  April 30, 2020
  ,
  May 4, 2020
  ,
  May 20, 2020
  ,
  June 10, 2020
  and
  June 12, 2020
  .
  (c)
  the description of the Company's
                                           American Depositary Shares, each representing forty (40) ordinary shares, no par value,
                                           included in the registration statement on
  Form 8-A
  filed on April 20, 2015 (File
                                           No. 001-37353) under the Securities Exchange Act of 1934, as amended (the "
  Exchange
                                           Act
  "), including any amendment or report filed for the purpose of updating
                                           such description.
  All documents or reports
  subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and to the extent designated
  therein, certain reports on Form 6-K, furnished by the Company, after the date of this Registration Statement and prior to the
  filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all
  securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement
  and to be part hereof from the date of filing of such documents or reports. Any statement in a document or report incorporated
  or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration
  Statement to the extent that a statement contained herein or in any other subsequently filed document or report which also is
  or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
  ITEM 4.
  DESCRIPTION OF SECURITIES
  Not applicable.
  ITEM 5.
  INTERESTS OF NAMED EXPERTS AND COUNSEL
  Not applicable.
  ITEM 6.
  INDEMNIFICATION OF DIRECTORS AND
                                           OFFICERS
  Under the Israeli Companies
  Law, 5759-1999, or the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the
  duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part,
  for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation
  is included in its articles of association. Our amended and restated articles of association include such a provision. The
  company may not exculpate in advance a director from liability arising from a breach of his or her duty of care in connection
  with a prohibited dividend or distribution to shareholders.
  2
  As permitted under the
  Israeli Companies Law, our amended and restated articles of association provide that we may indemnify an office holder in respect
  of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance
  of an event or following an event:
  ●
  a
                                           monetary liability incurred by or imposed on the office holder in favor of another person
                                           pursuant to a court judgment, including pursuant to a settlement confirmed as judgment
                                           or arbitrator's decision approved by a competent court. However, if an undertaking
                                           to indemnify an office holder with respect to such liability is provided in advance,
                                           then such an undertaking must be limited to events which, in the opinion of the board
                                           of directors, can be foreseen based on the company's activities when the undertaking
                                           to indemnify is given, and to an amount or according to criteria determined by the board
                                           of directors as reasonable under the circumstances, and such undertaking shall detail
                                           the abovementioned foreseen events and amount or criteria;
  ●
  reasonable litigation expenses,
                                           including reasonable attorneys' fees, which were incurred by the office holder
                                           as a result of an investigation or proceeding filed against the office holder by an authority
                                           authorized to conduct such investigation or proceeding, provided that such investigation
                                           or proceeding was (i) concluded without the filing of an indictment against such office
                                           holder and without the imposition on him of any monetary obligation in lieu of a criminal
                                           proceeding, (ii) concluded without the filing of an indictment against the office holder
                                           but with the imposition of a monetary obligation on the office holder in lieu of criminal
                                           proceedings for an offense that does not require proof of criminal intent, or (iii) in
                                           connection with a monetary sanction;
  ●
  reasonable litigation expenses,
                                           including attorneys' fees, incurred by the office holder or which were imposed
                                           on the office holder by a court (i) in a proceeding instituted against him or her by
                                           the company, on its behalf, or by a third party, (ii) in connection with criminal indictment
                                           of which the office holder was acquitted, or (iii) in a criminal indictment of which
                                           the office holder was convicted of an offense that does not require proof of criminal
                                           intent;
  ●
  expenses he or she incurs
                                           as a result of administrative proceedings that may be instituted against him or her under
                                           Israeli securities laws, if applicable, and payments made to injured persons under specific
                                           circumstances thereunder; and
  ●
  any other matter in respect
                                           of which it is permitted or will be permitted under applicable law to indemnify an office
                                           holder in the company.
  As permitted under the
  Israeli Companies Law, our amended and restated articles of association provide that we may insure an office holder against the
  following liabilities incurred for acts performed by him or her as an office holder:
  ●
  a breach of the duty of loyalty
                                           to the company, provided that the office holder acted in good faith and had a reasonable
                                           basis to believe that the act would not harm the company;
  ●
  a breach of duty of care to
                                           the company or to another person, to the extent such a breach arises out of the negligent
                                           conduct of the office holder;
  ●
  a monetary liability imposed
                                           on the office holder in favor of a third party;
  ●
  expenses he or she incurs
                                           as a result of administrative proceedings that may be instituted against him or her under
                                           the Israeli securities laws if applicable, and payments made to injured persons under
                                           specific circumstances thereunder; and
  ●
  any other matter in respect
                                           of which it is permitted or will be permitted under applicable law to insure the liability
                                           of an office holder in the company.
  3
  Under the Israeli Companies
  Law, a company may not indemnify, exculpate or insure an office holder against any of the following:
  ●
  a breach of the duty of loyalty,
                                           except for indemnification and insurance for a breach of the duty of loyalty to the company
                                           to the extent that the office holder acted in good faith and had a reasonable basis to
                                           believe that the act would not prejudice the company;
  ●
  a breach of duty of care committed
                                           intentionally or recklessly, excluding a breach arising out of the negligent conduct
                                           of the office holder;
  ●
  an act or omission committed
                                           with intent to derive illegal personal benefit; or
  ●
  a fine or forfeit levied against
                                           the office holder.
  Under the Israeli Companies
  Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board
  of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling
  shareholders have a personal interest, also by the shareholders.
  Our articles of association
  permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. The
  Company has obtained directors' and officers' liability insurance for the benefit of its office holders and intends
  to continue to maintain such coverage and pay all premiums thereunder up to to the fullest extent permitted by the Israeli Companies
  Law.
  In addition, we have entered
  into agreements with each of our directors and executive officers exculpating them, to the fullest extent permitted by law and
  our articles of association, and undertaking to indemnify them to the fullest extent permitted by law and our articles of association.
  This indemnification is limited to events determined as foreseeable by the board of directors based on our activities, and to
  an amount or according to criteria determined by the board of directors as reasonable under the circumstances. The maximum indemnification
  amount set forth in such agreements is limited to an amount which shall not exceed 25% of our net assets based on our most recently
  audited or reviewed financial statements prior to actual payment of the indemnification amount. Such maximum amount is in addition
  to any amount paid (if paid) under insurance and/or by a third-party pursuant to an indemnification arrangement. In the opinion
  of the SEC, indemnification of directors and office holders for liabilities arising under the Securities Act of 1933, however,
  is against public policy and therefore unenforceable.
  ITEM 7.
  EXEMPTION FROM REGISTRATION CLAIMED
  Not applicable.
  ITEM 8.
  EXHIBITS.
  See Exhibit Index following
  the signature page.
  ITEM 9.
  UNDERTAKINGS
  (a)
  The undersigned Registrant hereby
                                           undertakes:
  (1)
  To file, during any period in
                                           which offers or sales are being made, a post-effective amendment to this registration
                                           statement:
  (i)
  to include any prospectus required
                                           by Section 10(a)(3) of the Securities Act;
  (ii)
  to reflect in the prospectus
                                           any facts or events arising after the effective date of the Registration Statement (or
                                           the most recent post-effective amendment thereof) which, individually or in the aggregate,
                                           represent a fundamental change in the information set forth in the Registration Statement;
                                           and
  (iii)
  to include any material information
                                           with respect to the plan of distribution not previously disclosed in the Registration
                                           Statement or any material change to such information in the Registration Statement;
  provided, however,
  that
  paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment
  by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13
  or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement;
  (2)
  That,
                                           for the purpose of determining any liability under the Securities Act, each such post-effective
                                           amendment shall be deemed to be a new registration statement relating to the securities
                                           offered therein, and the offering of such securities at that time shall be deemed to
                                           be the initial
  bona fide
  offering thereof
  .
  4
  (3)
  To remove from registration by
                                           means of a post-effective amendment any of the securities being registered which remain
                                           unsold at the termination of the offering.
  (b)
  The undersigned Registrant hereby
                                           undertakes that, for purposes of determining any liability under the Securities Act,
                                           each filing of the Registrant's annual report pursuant to Section 13(a) or Section
                                           15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit
                                           plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated
                                           by reference in the registration statement shall be deemed to be a new registration statement
                                           relating to the securities offered therein, and the offering of such securities at that
                                           time shall be deemed to be the initial
  bona fide
  offering thereof.
  (c)
  Insofar as indemnification for
                                           liabilities arising under the Securities Act may be permitted to directors, officers
                                           and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise,
                                           the Registrant has been advised that in the opinion of the Securities and Exchange Commission
                                           such indemnification is against public policy as expressed in the Securities Act and
                                           is, therefore, unenforceable. In the event that a claim for indemnification against such
                                           liabilities (other than the payment by the Registrant of expenses incurred or paid by
                                           a director, officer or controlling person of the Registrant in the successful defense
                                           of any action, suit or proceeding) is asserted by such director, officer or controlling
                                           person in connection with the securities being registered, the Registrant will, unless
                                           in the opinion of its counsel the matter has been settled by controlling precedent, submit
                                           to a court of appropriate jurisdiction the question whether such indemnification by it
                                           is against public policy as expressed in the Securities Act and will be governed by the
                                           final adjudication of such issue.
  5
  EXHIBIT INDEX
  Exhibit
  Number
  Description
  4.1
  Amended and Restated Articles of Association of the Registrant (incorporated by reference to Exhibit 1.1 of the annual report on Form 20-F filed with the Securities and Exchange Commission on June 12, 2020).
  5.1
  Opinion of Pearl Cohen Zedek Latzer Baratz.
  5.2
  Opinion of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co.
  23.1
  Consent of  Pearl Cohen Zedek Latzer Baratz (included in Exhibit 5.1).
  23.2
  Consent of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co. (included in Exhibit 5.2).
  23.3
  Consent of Kost Forer Gabbay and Kasirer, Certified Public Accountant (Isr.), a member of Ernst & Young Global.
  24.1
  Power of Attorney (included on signature page).
  99.1
  The 2005 Israeli Share Option Plan (incorporated by reference to Exhibit 4.1 of the annual report on Form 20-F filed with the Securities and Exchange Commission on June 12, 2020).
  99.2
  The 2018 Israeli Share Option Plan (incorporated by reference to Exhibit 4.2 of the annual report on Form 20-F filed with the Securities and Exchange Commission on June 12, 2020).
  6
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
  duly authorized, in the City of Jerusalem, State of Israel, on this 22nd   day of June, 2020.
  BiondVax Pharmaceuticals
      Ltd.
  By:
  /s/
      Ron Babecoff
  Ron Babecoff
  Chief Executive
      Officer
  POWER OF ATTORNEY
  KNOW ALL BY THESE PRESENTS,
  that each individual whose signature appears below constitutes and appoints Ron Babecoff and Uri Ben Or, and each of them, his
  true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him and in his name, place
  and stead, in any and all capacities, to sign this registration statement and any and all future amendments (including post-effective
  amendments) to the registration statement, and to file the same with all exhibits thereto, and all documents in connection therewith,
  with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, and each of them, full power and authority
  to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents
  and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any
  of them, or their or his substitute, may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements
  of the Securities Act of 1933, as amended this registration statement has been signed by the following persons in the capacities
  and on the dates indicated:
  Signatures
  Title
  Date
  /s/
      Mark Germain
  Chairman of the Board of Directors
  June 22, 2020
  Mark Germain
  /s/
      Ron Babecoff
  Chief Executive Officer and
      Director
  June 22, 2020
  Ron Babecoff
  /s/
      Uri Ben Or
  Chief Financial Officer
  June 22, 2020
  Uri Ben Or
  /s/
      Avner Rotman
  Director
  June 22, 2020
  Avner Rotman
  /s/
      Yael Margolin
  Director
  June 22, 2020
  Yael Margolin
  /s/
      George H. Lowell
  Director
  June 22, 2020
  George H. Lowell
  /s/
      Morris Laster
  Director
  June 22, 2020
  Morris Laster
  /s/
      Ruth Ben Yakar
  Director
  June 22, 2020
  Ruth Ben Yakar
  /s/
      Issac Devash
  Director
  June 22, 2020
  Issac Devash
  /s/
      Adi Raviv
  Director
  June 22, 2020
  Adi Raviv
  /s/
      Samuel Moed
  Director
  June 22, 2020
  Samuel Moed
  Puglisi &
      Associates
  Authorized U.S.
      Representative
  By:
  /s/
      Donald Puglisi
  Name:
  Donald Puglisi
  Title:
  Managing Director
  June 22, 2020
  7